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Edited by Hans EklundAbstract Non-bullous congenital ichthyosis erythroderma
(NCIE) and lamellar ichthyosis (LI) are characterized by muta-
tions in 12R-lipoxygenase (12R-LOX) and/or epidermal lipoxy-
genase 3 (eLOX3) enzymes. The eLOX3 lacks oxygenase
activity, but is capable of forming hepoxilin-type products from
arachidonic acid-derived hydroperoxide from 12R-LOX, termed
12R-hydroperoxyeicosa-5,8,10,14-tetraenoic acid (12R-HpETE).
Mutations in either of two enzymes lead to NCIE or LI. More-
over, 12R-LOX-deﬁcient mice exhibit severe phenotypic water
barrier dysfunctions. Here, we demonstrate that 12R-HpETE
can also be transformed to 8R-HXA3 by hepoxilin A3 (HXA3)
synthase (12-lipoxygenase), which exhibits oxygenase activity.
We also presented a novel form of ichthyosis in a patient, termed
hepoxilin A3 synthase-linked ichthyosis (HXALI), whose scales
expressed high levels of 12R-LOX, but were deﬁcient of HXA3
synthase.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Non-bullous congenital ichthyosiform erythroderma
(NCIE) is a special form of autosomal recessive congenital ich-
thyoses (ARCIs), which covers a heterogeneous group of
hereditary keratinization disorders that are linked with hyper-
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HXALI, hepoxilin A3 synthase-linked ichthyosis; LI, lamellar ichthy-
osis; 12R-LOX, 12R-lipoxygenase; NCIE, non-bullous congenital
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doi:10.1016/j.febslet.2007.12.017skin [1]. NICE aﬀects males and females equally, and is hall-
marked by prominent erythroderma, thick and semiadherent
scaly skin, predominantly in ﬂexures, and persists throughout
life. In severe cases, the child may be stillborn or born as a har-
lequin foetus or a colloidon baby. Histologic features reveal an
increase in stratum corneum thickness, a prominent granular
layer, and enhanced mitoses pinpointing a hyperproliferative
epidermal defect [2,3]. Recent genetic studies identiﬁed two
causative genes 12R-lipoxygenase (12R-LOX) and epidermal
lipoxygenase 3 (eLOX3) linked to chromosome 17, which
can lead to NCIE [4,5]. These authors also postulated that
product of one of these enzymes (12R-LOX) may serve as sub-
strate for the other (eLOX3), thus functioning in the same met-
abolic pathway [4]. Yu et al. [6,7] showed that eLOX3, which
does not exhibit any oxygenase activity, operates as an epoxy
alcohol synthase utilizing preferably the product from 12R-
LOX, termed 12R-hydroperoxyeicosa-5,8,10,14-tetraenoic
acid (12R-HpETE) as substrate, thus providing for the ﬁrst
time a clear-cut evidence for a functional linkage of proteins
12R-LOX and eLOX3. Both proteins 12R-LOX and eLOX3
are coexpressed in tissues, and mutations in any of the two
causative genes can lead to NCIE [4]. In a recent study, Epp
et al. [8] demonstrated severe phenotypic water barrier dys-
function in 12R-LOX-deﬁcient mice, causing death of mice
within 3–5 h after the birth. However, barrier function of tight
junctions in these mice remained unaﬀected. Also, no compen-
satory epidermal hyperproliferation or hyperkeratoses, which
are frequently observed in patients with ichthyosiforms, were
registered in 12R-LOX-deﬁcient mice. In the present case
report, we have shown that skin of a patient with ichthyosis,
usually found only in the male sex and characterized by dark
and semiadherent scaling with rhombic appearance, is almost
devoid of eLOX3, but overexpresses 12R-LOX. Strikingly,
patient skin is also devoid of hepoxilin A3 (HXA3) synthase,
an enzyme, recently identiﬁed by us in human platelets and
rat insulinoma cells, which possesses oxygenase activity and
is responsible for the conversion of 12R- and 12S-hydroperox-
ides of arachidonic acid (AA) into 8R/S-HXA3 [9]. Evidence
for the synthesis of 8R/S-HXA3 in vitro was presented upon
treatment of 12R-HpETE with recombinant rat HXA3 syn-
thase and with human platelet-type 12S-LOX, but not with
porcine-type 12S-LOX. In conclusion, our studies demonstrate
that the formation of HXA3 is inevitably required to avoid
water barrier dysfunction in various ARCIs. Therefore, any
defect in 12R-LOX–eLOX3 or in the 12R-LOX–HXA3blished by Elsevier B.V. All rights reserved.
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and lead to hepoxilin A3 synthase-linked ichthyosis (HXALI)
and possibly other forms of ARCIs.2. Materials and methods
2.1. Patient
A 63-year-old male patient with ichthyosis presented for investiga-
tion of molecular mechanisms of the disease in the light of recent ge-
netic studies related to 12R-LOX and eLOX3 gene defects in NICE.
Ichthyosis started in infancy around 1–2 years. In the beginning mild
symptoms, such as light scaling, were found on the lower legs and low-
er arms. With growing age the scaling became dark brown, thick and
more adherent (Fig. 1A and B). Histologically, mild hyperkeratosis,
thinned and occasionally missing granular layer, but also broadened
and thickened granular layer and mild to increased atrophy of the epi-
dermis are observed (Fig. 1C). However, the body folds, such as ante-
cubital and popliteal folds as well as palms are spared from scaling. No
other X-linked diseases, such as the Kallman syndrome or anosmia
were observed throughout life. In the last 10 years patient has been fre-
quently therapied against sarcoidosis and bronchial asthma with corti-
costeroid (10 mg), which apparently worsened the scaling process.
Diagnosis of ichthyosis was established by testing deﬁciency of steroid-
sulphatase and therefore accumulation of high levels of cholesterol
sulphate in the scales [10]. A 55-year-old male healthy subject served
as a match control for this study.2.2. Materials
Rneasy kit and QIA shredder were purchased by QIAGEN GmbH
(Hilden, Germany), Expand Reverse Transcriptase (50 U/ll) from
Roche Diagnostics (Paris, France), Random Primers and RNAse free
ddH2O from Invitrogen GmbH (Karlsruhe, Germany), Taq polymer-Fig. 1. HXALI patient (63 years of age): (A) extensive ichthyosis in right arm
epidermal scales from the patient. Ripped-out scales were ﬁxed using 4% para
Texas Red-X phalloidin.ase from Invitek GmbH (Berlin, Germany). Primers for 12R-LOX,
eLOX3 and HXA3 synthase were purchased from TIB molbiol (Berlin,
Germany).
2.3. Immunoﬂuorescence microscopy
Ripped-out Scales were ﬁxed using 4% paraformaldehyde and after
two washings with PBS stained with Hoechst 33342 (Boehringer
Mannheim, Germany) for epidermal cells and Texas Red-X phalloidin
for actin. Cells were visualized under the ﬂuorescence microscope
(Olympus BX 40, Japan). For immunoﬂuorescence microscopy (IF)
microscopy of 12R-LOX, eLOX3 and HXA3 synthase paraﬃn sections
of epidermal scales or bioptic skin from healthy subjects were perme-
abilized in PBS containing 1% BSA and 0.05% TX-100 for 5 min. Fol-
lowing 3 · 10 min washings with PBS and 1% BSA, samples were
incubated with primary antibodies against rat 12R-LOX (Abnova, Tai-
pei, Taiwan), Leukocyte-type 12S-LOX (Cayman Europe, Tallinn,
Estonia), and eLOX3 (1:100 to 1:250 dilutions) at room temperature
for 1 h in PBS/1% BSA. Tissue sections were then incubated for 1 h
with secondary FITC antibodies (Santa Cruz Biotechnology Inc., Hei-
delberg, Germany) (1:250 dilution) in PBS/1% BSA in the dark. Tissue
samples after washing with PBS/1% BSA were visualized using ﬂuores-
cence microscope (Olympus BX 40, Japan).
2.4. Expression of recombinant eLOX3 protein
For transient expression 14 lg of eLOX3 expression constructs or
the lacZ expression construct were introduced into HEK 293 cells
(seeded at 1.4 · 106 cells per 100 mm plate) using the Calphos Mam-
malian Transfection Kit according to manufacturers protocol (BD
Biosciences Clontech, Palo Alto, CA). Cells were harvested 48 h after
transfection, washed with phosphate-buﬀered saline and homogenized
by sonication (Bandelin Sonopuls, three times 10 pulses for 1 s, 40%
eﬃciency) in incubation buﬀer (50 mM Tris/HCl, 1 mM EDTA,
1 mM EGTA, 10 lg/ml leupeptin, pH 7.4). Cell lysates were assayed
for protein content using Bio-Rad protein assay dye reagent (Bio-
Rad, Mu¨nchen, Germany).; (B) dry skin with superﬁcial cracking in right leg; (C) IF microscopy of
formaldehyde and stained with Hoechst 33342. Actin was stained with
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For recombinant rat 12S-LOX expressing HXA3 synthase activity
12S-LOX cDNA was cloned into pPICZ, th plasmid linearized
and electroporated into P. pastoris GS115 cells. For details see [9].
Stroma-freeLysate supernatant of these cells was used as enzyme
source.
For recombinant rat HXA3 synthase wild type 12S-LOX was
expressed in Escherichia coli as His-tagged fusion proteins. For puriﬁ-
cation see details in [9]. After Ni-agarose column step the enzyme was
enriched to 90% of the activity. For further puriﬁcation by anion-ex-
change chromatography it was loaded on a Q-Sepharose column
(Amersham Biosciences, Germany) and eluted with KCl. The ﬁnal
enzyme exhibited an activity of more than 97%. The recombinant
HXA3 synthase (see Section 2) showed a solitary band on SDS–PAGE
with a mol. wt. of 75 kDa. Kinetic analysis of the enzyme showed Km
values of 20.5 and 91.5 lM and Vmax values of 22.2 and 1.34 s
1 for
AA and 12S-HpETE, respectively [9].2.6. Immunoblot analysis
Immunoprecipitation was performed by incubating 200 lg protein
overnight with anti-rabbit polyclonal eLOX3 antibody in a dilution
of 1:500. Following addition of 100 ll of prewashed protein G
agarose beads (Biomol, Hamburg, Germany) samples were incubated
for 1 h at RT. After washing with ice cold PBS, 40 ll of Roti-
Load sample buﬀer (Roth, Germany) were added and the mixture
boiled for 5 min. Supernatants were subjected to immunoblot analy-
sis. Brieﬂy, immunoprecipitate was electrophoresed on 10% SDS–
PAGE, and proteins were semi-dry transferred onto Protran BA83
cellulose nitrate Membranes (Schleicher and Schuell, Germany).
Equal loading/transfer was conﬁrmed by Ponceau staining of the
membranes. Membranes were blocked overnight in Tris buﬀered sal-
ine (20 mM Tris/HCl, 150 mM NaCl, pH 7.6) with 0.05% Tween 20
(TBS/T) containing 5% non-fat dry milk. Incubations with primary
and secondary antibodies were performed in TBS/T containing 5%
non-fat dry milk for 1 h. After incubation with antibodies, mem-
branes were washed in TBS/T. ECL Western Blotting Detection
Kit (Santa Cruz Biotechnology, Heidelberg, Germany) was used
for detection.
Rabbit polyclonal anti-peptide antibodies were raised against pep-
tides corresponding to 23 amino acids (167–189) of the unique extra
subdomains of eLOX3, respectively. The antibody speciﬁcally recog-
nizes recombinant human and mouse eLOX3. The antibodies do not
show cross-reactivity with any other LOX isoenzymes (P. Krieg,
unpublished work). Other primary antibody used was goat anti-actin
(sc-1616, Santa Cruz Biotechnology, Santa Cruz, CA).
Secondary antibodies were horseradish peroxidase-conjugated anti-
rabbit (BD Biosciences, Pharmingen, Palo Alto, CA).Fig. 2. Expression of HXALI-speciﬁc transcripts by RT-PCR in scales
of a patient and bioptic skin of a healthy subject. Total RNA (1 lg)
was extracted and RT-PCR analysis was performed for: (A) 12R-LOX
(upper panel), as well as for GAPDH (lower panel), and (B) eLOX3
(upper panel) and GAPDH (lower panel). GAPDH served as a control
to ensure that RNA amounts were equal. PCR data are representative
of three separate experiments.2.7. RT-PCR analysis
Scales (200 mg) from the patient were ripped-out carefully with
pinceps and collected in a sterile sample vial. Punch biopsy of skin
from a female healthy subject served as control for this study. Total
RNA was isolated from the tissue sample using Rneasy kit from Qia-
gen (Hilden, Germany). RNA (1 lg) was reverse transcribed at 42 C
for 60 min with 150 pmol of random primer and 15 U of AMV reverse
transcriptase (Roche Applied Science, Germany). For ampliﬁcation of
HXA3 synthase cDNA, 1 ll of reverse transcription reaction mixture
was used together with following primers: (a) human 12R-LOX: 5 0-
CgTggAAgAggCTgAAggACA-3 0 and 5 0-gggTTgACgCCgTTgAgg-
TA-3 0 (annealing temperature: 66 C, size: 126 bp), (b) leukocyte type
12S-LOX: 5 0-TTgAACATTCCCACCACg-3 0 and 5 0-AggCACTCTg-
TTTgAAgC-3 0 (annealing temperature: 54 C, size: 632 bp), (c) human
eLOX3: 5 0-TggAgTTTTTAAAgggTgAC-3 0 and 5 0-TCCgTAgTTCA-
TATTgCCTAT-3 0 (annealing temperature: 56 C, size: 650 bp), (d)
human GAPDH: 5 0-TCCATgACAACTTTggTATCgTgg-3 0 and 5 0-
gACgCCTgCTTCACCACCTTCT-3 0 (annealing temperature: 62 C,
size: 307 bp). After initial denaturing for 2 min at 95 C, 30 cycles of
PCR were performed. Each cycle consisted of a denaturing period
(1 min at 94 C), an annealing phase (1 min), and a synthesis phase
(1 min at 72 C). After the last cycle, sample was incubated for another
10 min at 72 C. PCR products were separated on 2% agarose gel, and
DNA bands were stained with ethidium bromide and visualized under
UV light.2.8. HXA3 synthase activity assay
Incubations with 30 ll of supernatant from scale lysate and 50 lg
12R- or 12S-HpETE were performed in a buﬀer (50 mM Tris,
150 mM NaCl, pH 7.4) making a total volume of 500 ll. HXA3 syn-
thase activity was measured by repetitive scanning in the range of
230–250 nm by monitoring disappearance of 12R- or 12S-HpETE sig-
nal (max absorption) at 240 nm in the time-drive mode. For positive
control recombinant rat HXA3 synthase (0.03 lM) instead of superna-
tant of scale lysate was used in the above incubation mixture. After
stopping the reaction mixture it was acidiﬁed to pH 3.0 and lipids were
extracted with three volumes of ethyl acetate. For high performance
liquid chromatography (HPLC) puriﬁcation and gas chromatogra-
phy–mass spectrometry (GC–MS) analysis see below.
2.9. Reverse and chiral phase HPLC
Products of 12R-HpETE–HXA3 synthase reactions were puriﬁed by
RP-HPLC with a Phenomenox C18 5 lm column (0.46 · 25 cm) eluted
at a ﬂow rate of 1 ml/min with methanol:water:acetic acid (75:25:0.01,
v/v) using a Shimadzu diode array detector CBM-10A. For chiral
phase HPLC a LC(R)-DNB-PG column (0.46 · 25 cm, Supelco, Ger-
many) was employed. n-Hexane:isopropanol (96:4, v/v) was used as
solvent system at a ﬂow rate of 1 ml/min. Authentic standards of
8R- and 8S-HXA3 were kind gifts from Dr. Pace-Asciak, Toronto,
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Arbor, MI).
2.10. GC–MS analysis
Free fatty acids (hepoxilins and other LOX-metabolites) were ﬁrst
converted to methyl esters by adding 300 ll ethereal diazomethane.
After 15 min of incubation the solvent was evaporated under nitrogen
stream, and 50 ll of N-methyl-N(trimethylsilyl)-triﬂuoroacetamide
were added and heated for 1 h. GC–MS analysis was carried out on
a Saturn 4D GC–MS–MS system (Varian, Darmstadt, Germany)
equipped with a Supelco DB5-MS column (30 m · 0.25 mm;
0.25 lm). Samples were injected at 150 C, and after 1 min pro-
grammed to 250 C at 10 C/min, followed by an isothermic post-run
for 20 min. The injector and transfer line temperatures were adjusted
at 230 and 250 C, respectively.3. Results
RT-PCR analysis (Fig. 2A) showed enhanced expression of
12R-LOX mRNA in scales isolated from the patient with ich-
thyosis. In comparison, very little wild-type 12R-LOX mRNA
was detected in skin of healthy subject. For synthesis of HXA3
a functional relationship between 12R-LOX and eLOX3 is re-
quired, whereby the 12R-LOX product, 12R-HpETE, serves as
substrate for the hydroperoxide isomerase eLOX3. However,
RT-PCR and immunoblot analyses showed the absence of
eLOX3 in scales of the patient as compared to normally ex-
pressed eLOX3 mRNA (Fig. 2B) or protein (Fig. 3A and B
showing the speciﬁcity of protein detected) in a healthy subject.
The diﬀerences in expression of 12R-LOX, eLOX3 and HXA3
synthase (12S-LOX) in scales of patient and of the healthy
subject was also conﬁrmed by immunoﬂuorescence using spe-HEALTHY 
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Fig. 3. Absence of eLOX3 in HXALI scales as compared with healthy epid
HXARI scales or bioptic healthy epidermis. The precipitate was electrophor
antibody raised against peptides corresponding to 23 amino acids (167–189
eLOX3 recombinant protein was transiently expressed in HEK cells and imciﬁc antibodies against these enzymes (Fig. 4). The antibody
raised against rat 12S-LOX (HXA3 synthase) recognized also
human epidermal 12S-LOX (HXA3 synthase). As mutated
eLOX3 is still expressed at the protein level in cells [7,8], these
ﬁndings suggest to us that the patient in the case study has a
diﬀerent ichthyosis form than that reported for NCIE patients,
who showed deﬁciency of 12R-LOX or eLOX3 due to gene
mutations [5–7].
Since mutation in 12R-LOX gene has recently been shown to
disrupt the formation of epidermal permeability barrier, it was
evident why skin pathobiology of patient with HXALI, who is
deﬁcient of eLOX3, but not 12R-LOX, is distinct from that of
NCIE patients. We therefore hypothesized that in addition to
12R-LOX the HXA3 synthase, that converts 12S-HpETE to
8S-HXA3, is inevitably required to maintain epidermal perme-
ability barrier function. HXA3 synthase was recently identiﬁed
by us as an intrinsic activity in rat leukocyte-type and platelet-
type 12S-LOXs, but not in porcine leukocyte-type 12S-LOX
or rabbit leukocyte-type 15S-LOX [9]. Taking this for granted,
mutations in any of the gene products 12R-LOX, eLOX3 or
HXA3 synthase would de facto lead to HXALI and/or other
ARCIs. Nevertheless, a prerequisite action of HXA3 synthase
in healthy subjects is to convert R-isoform of 12-HpETE to
8R-HXA3, which was till todate ruled out [12]. We therefore
ﬁrst investigated if the recombinant rat HXA3 synthase
in vitro would transform 12R-HpETE to 8R-HXA3. Indeed,
upon incubation of 12R-HpETE with recombinant enzyme
for 1 h at pH 7.4, 8R-HXA3 formation could be identiﬁed
by chiral-phase HPLC and GC–MS–MS. The electron
impact-mass spectrum (EI-MS) of HXA3, as the methyl es-
ter–trimethylsilyl ether derivative showed 407 [M+15], 281
LO
X-
3
cZ
3
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eLOX-3
actin
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eLla
B
ermis. Immunoprecipitation was performed with 200 lg protein from
esed as described in Section 2. eLOX3 was detected by using a speciﬁc
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munoblotted as described in Section 2 (B).
Fig. 4. IF microscopy of 12R-LOX, eLOX3 and HXA3 synthase in epidermal scales from the patient and in the bioptic skin from healthy subject.
Paraﬃn sections of epidermal scales or bioptic skin from healthy subjects were permeabilized with 0.05% TX-100 for 5 min and incubated with
primary antibodies against 12R-LOX, Leukocyte-type 12S-LOX, and eLOX3 (1:100 to 1:250 dilutions) at room temperature for 1 h. Tissue sections
were then incubated with secondary FITC antibodies (1:250 dilution) as described in Section 2. Tissue samples were visualized using ﬂuorescence
microscope under UV excitation.
Fig. 5. RT-PCR analysis of HXA3 synthase in scales of HXALI
patient and in bioptic tissue of a healthy subject. For methodological
procedure see legend in Fig. 2.
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+ and 243 [CH3CO2C6H10-
CHOSi(CH3)3]
+ as characteristic mass fragments (Table 1).
The product is identical to that reported by Yu et al. [6], i.e.
8R-hydroxy-11R,12R-epoxyeicosa-5Z,9E,14Z-trienoic acid
(8R-HXA3). That HXA3 synthase exhibits a novel action in
the epidermis is underscored by its inherent oxygenase activity,
shown by the characteristic mass fragment 295 of 12-HETE, a
product of AA oxygenation (Table 1). The oxygenase activity
is absent in eLOX3. The conﬁrmation for 8R-HXA3 formation
was further documented by monitoring the genuine decay of
12R-HpETE signal at 240 nm by repetitive scanning in the
range 230–250 nm (not shown).
Intriguingly, the in vitro formation of 8R-HXA3 from 12R-
HpETE by HXA3 synthase pinpointed that pathogenesis of
HXALI is causative of HXA3 synthase deﬁciency, and thus
distinct from that of NCIE. Indeed, RT-PCR analysis of scales
from HXALI patient did not show any HXA3 synthase expres-
sion as compared with the bioptic tissues from healthy sub-
jects, which exhibited both HXA3 synthase (Fig. 5) and
eLOX3 (Figs. 2B and 3). Also, no disappearance of 12R-
HpETE signal at 240 nm in the time-drive mode was observedTable 1
Representative mass fragments of Me-TMS derivatives of HXA3 and
12-HETE obtained from the transformation of 12R-HpETE by rat
HXA3 synthase
Eicosanoid Characteristic mass fragment (EI mode)
8R-HXA3 407 [M
+15]
281 [HCOSi(CH3)3C2H2C2H2OC8H15]
+
243 [CH3CO2C6H10CHOSi(CH3)3]
+
12-HETE 391 [M+15]
295 [C4H4 Æ CH(OTMSi) Æ C6O2H13]
+
Recombinant rat HXA3 synthase (30 nM) was incubated with 50 lg
12R-HpETE in 500 ll PBS at 37 C for 30 min. Lipids were extracted,
puriﬁed by HPLC and assayed Me-TMS derivatives by GC–MS as
described earlier [9].in scales of HXALI patient because of the absence of HXA3
synthase (not shown).4. Discussion
Our studies demonstrate for the ﬁrst time that synthetic
pathway for the formation of HXA3 through 12R-LOX and
eLOX3 or through 12R-LOX and HXA3 synthase pathway
must be in tact for NCIE or HXALI disease-free skin. Muta-
tion in any of three genes 12R-LOX, eLOX3 or HXA3 syn-
thase may lead to aforementioned diseases without
alterations in proliferation and organisation of keratinocytes
in stratum corneum. To these genes can be added a novel cyto-
chrome P450 gene FLJ39501 on chromosome 19p 12, recently
reported by Lefe´vre et al. [11]. FLJ39501 encodes a protein
CYP4F2 homologue of leukotriene B4-x-hydroxylase, which
catalyzes 20-hydroxylation of trioxilin A3 (20-OH-(R)TrXA3)
284 S. Nigam et al. / FEBS Letters 582 (2008) 279–285obtained through 12R-LOX pathway. Further oxidation of 20-
OH-(R)TrXA3 by fatty alcohol:nicotinamide–adenine dinucle-
otide oxidoreductase (FAO) enzyme complex leads to 20-
COOH-(R)TrXA3, which is essentially missing in most forms
of ARCIs. The oxidation product 20-COOH-(R)TrXA3 hereto
is involved in skin hydration and its (S)-homologue in spastic
paraplegia [11]. Together, these ﬁndings provide a clear-cut
evidence for a functional linkage either of proteins 12R-
LOX, eLOX3 and CYP4F2 and/or 12R-LOX, HXA3 synthase
and CYP4F2. The proteins 12R-LOX and eLOX3 are coex-
pressed in tissues, and mutations in any of the two causative
genes can lead to NICE [4], whereas mutations in FLJ39501
have been shown to cause Sjo¨gren–Larsson syndrome, charac-
terized by lamellar ichthyosis and paraplegia [11].
In contrast to eLOX3, which does not exhibit any oxygenase
activity, rat HXA3 synthase, a variant of rat leukocyte-type
12S-LOX, does express oxygenase activity (Fig. 3B). This
activity is impaired when positional speciﬁcity of AA was
altered [9]. In HXA3 synthase amino acid Leu353 was found
to be crucial sequence determinant for AA oxygenation [12],
and not the conventional sequence determinants Met419 and
Ile418 as shown for porcine leukocyte-type 12S-LOX, human
platelet-type 12S-LOX or rabbit leukocyte-type 15S-LOX-1
[13]. Site-directed mutagenesis on conventional determinants
Met419 and IIe418 in HXA3 synthase illustrated that mutants
of HXA3 synthase exhibited although reduced HXA3 forma-
tion, but 12-LOX activity was always retained as shown by
the formation of 12-HETE [13]. In contrast, platelet-type
and porcine leukocyte-type 12-LOXs altered their activity to
that of 15S-LOX with 15-HETE as the main product.
The regulation of HXA3 formation is also dependent on cel-
lular overall peroxide tone. Glutathione peroxidases (GPxs)
compete with HXA3 synthase for 12S-HpETE as substrate
either to reduce it to 12S-HETE or to convert it to HXA3.
NCIE and HXALI are skin proliferative diseases, e.g. psoria-
sis, and skin lesions show augmented formation of reactive
oxygen species and insuﬃcient antioxidant activity [14]. Conse-
quently, enhancement of antioxidant activity expressed by cel-
lular glutathione peroxidases has been shown to suppress
epidermal hyperproliferation in psoriasis patients [15].
Obviously, increased levels of 12R-HpETE in HXALI
patients, resulting from the overexpression of 12R-LOX and
diminished glutathione peroxidase activity, are seemingly not
only responsible for hyperproliferation and reorganisation of
stratum corneum (scale formation), but also for mild expres-
sion of the disease in comparison to patients with NCIE or
with lamellar ichthyosis type-3. Severe NCIE may also exhibit
mutations in the transglutaminase-1 (TGM-1) gene [16], and
be associated with growth retardation, oligophrenia, spastic
paralysis, genital hypoplasia, hypotrichia and shortened life
expectancy [17]. Recessive lamellar ichthyosis (LI) is consid-
ered as synonymous with NCIE. It shows whitish–grayish
scaling including squamous pytriasiform appearance, histopa-
thological features revealing hyperkeratosis, mild thickening of
the stratum corneum. Also observed is mild perivascular
lymphocytic inﬁltrate in epidermis with dilation of capillaries
[11]. HXALI patient does not exhibit any of these symptoms,
obviously because of the overexpression of 12R-LOX. Fur-
thermore, it has been reported that in mice deﬁcient of 12R-
LOX processing of proﬁlaggerin to ﬁlaggrin, which aggregates
keratin ﬁlaments to form macroﬁbrils in corniﬁed cells of the
stratum corneum, is impaired, resulting in decreased integrityof the corniﬁed envelop [8]. Reduced proteolytic processing
of ﬁlaggrin in humans has been shown to cause ichthyosis vul-
garis [18]. In mice with ablated 12R-LOX gene are also shown
signiﬁcant alterations in ester-bound ceramides, which play a
crucial role in the barrier function of epidermis [19]. Neither
processing of proﬁlaggerin to ﬁlaggrin nor any diﬀerence in
the level of ceramides were observed in HXALI patient when
compared with those in healthy subjects (not shown).
In conclusion, although several assumptions and hypothesis
have yet to be proved experimentally, specially manifestation
of disease by comparison of AA metabolites of 12R-LOX–
eLOX3 or 12R-LOX–HXA3 synthase pathways in skin sam-
ples of a group of HXALI patients with those of healthy skin
samples, there is no doubt that the defect in the formation of
HXA3 via 12R-LOX–HXA3 synthase uncovers a novel path-
way for identifying another biochemical link to explain the
pathogenesis of HXALI disease in addition to already known
mutations in NCIE, lamellar ichthyosis and Sjo¨gren–Larsson
syndrome. Which pivotal roles are played by mutations in
12R-LOX–eLOX3 or 12R-LOX–HXA3 synthase pathways in
skin disorders, such as Refsum disease, which involves ichthy-
osis and progressive neurologic dysfunction, or Nethertons
syndrome, which involves autosomal recessive ichthyosis, hair
shaft abnormality and atopy, are topics for future studies.
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